Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia

BACKGROUND: Current conventional chemotherapy for acute myeloid leukemia (AML) can achieve remission in over 70% of patients, but a majority of them will relapse within 5 years despite continued treatment. The relapse is postulated to be due to leukemia stem cells (LSCs), which are different from no...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Jianbiao, Bi, Chonglei, Ching, Ying Qing, Chooi, Jing-Yuan, Lu, Xiao, Quah, Jessie Yiying, Toh, Sabrina Hui-Min, Chan, Zit-Liang, Tan, Tuan Zea, Chong, Phyllis SY, Chng, Wee-Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504806/
https://www.ncbi.nlm.nih.gov/pubmed/28693523
http://dx.doi.org/10.1186/s13045-017-0507-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504806/
https://www.ncbi.nlm.nih.gov/pubmed/28693523
http://dx.doi.org/10.1186/s13045-017-0507-y

Ejemplares similares